Volume : 13, Issue : 07, July – 2026

Title:

IMPLEMENTATION OF ALOCA PRINCIPLES FOR DATA INTEGRITY IN PHARMACEUTICAL DOCUMENTATION

Authors :

Sayed Shaffath Ali, Pole Vijay, Shaik Akhil Pasha, Dr. Shaik Shabeer, Dr. P Poli Reddy

Abstract :

Data integrity is critical to regulatory compliance, and the fundamental reason for 21 CFR Part 11 published bythe U.S. Food and Drug Administration (FDA). FDA published the first guideline in 1963, and since then FDA and European Union (EU) have published numerous guidelines on various topics related to dataintegrity for the pharmaceutical industry. Regulators wanted to make certain that industry capture accurate data during the drug development lifecycle and through commercialization consider the number of warning letters issued lately by inspectors across the globe on data integrity.
This article discusses the history of regulations put forward by various regulatory bodies, the term ALCOA Plus adopted by regulators, the impact of not following regulations, and some prevention methods by using some simple checklists, self-audit, and self-inspection techniques. FDA uses the acronym ALCOA to define its expectations of electronic data. ALCOA stands for Attributable, Legible, Contemporaneous, Original, and Accurate. ALCOA was further expanded to ALCOA Plus, and the Plus means Enduring, Available and Accessible, Complete, Consistent, Credible, and Corroborated.
To prevent data integrity, various solutions can be implemented such as a simple checklist for various systems, self-audit, and self-inspections. To do that we haveto develop strategy, people, implement better business processes, and gain a better understanding of data lifecycle as well as technology. Pharmaceutical industry ensures that data entered for various steps of drug development is accurate so that we can have confidence that the drugs produced by the industry are within some parameters. The regulations put forward by FDA and EU are not new. The first regulation was published in 1963, and after that regulators published multiple guidelines.(1)
Keywords: Data Integrity regulations ALCOA self-aud itself-inspection checklist USFDA, MHRA

Cite This Article:

Please cite this article in press Sayed Shaffath Ali et al., Implementation of aloca principles for Data Integrity In Pharmaceutical Documentation, Indo Am. J. P. Sci, 2026; 13(07).

REFERENCES:

1. RattanAK.DataIntegrity:History,Regulations,andImplementationofALCOA Plus in Pharmaceutical Industries. Journal of GXP Compliance. 2017;21(4)1-12.
2. Science Direct. Ensuring data integrity: best practices and strategies in pharmaceutical industry. Science Direct; 2025 . Science Direct
3. Schniepp SJ. ALCOA+
and data integrity.
Pharmaceutical Technology. 2019;43(10):77-80. Pharmaceutical Technology
4. M C Tayade Data IntegrityViolations in thePharmaceutical Industryand Regulatory Measures January, 2023; Revised: 13th March, 2023; Accepted: 10th May, 2023: 25th June, 2023
5. European Commission. EudraLex: The rules governing medicinal products in the European Union. Volume 4: EU guidelines for good manufacturing practice formedicinal products for human and veterinary use. Chapter 4: Documentation. Brussels: European Commission; 2011.
6. The European Qualified Person: Legal Accountability, Quality Leadership, and AI Integration in Modern Pharmaceutical Manufacturing PDA Journal of Pharmaceutical Science and Technology March 2026, 80 (2) 239-247; DOI
7. PIC/S. Guidance on Good Documentation Practices and Data Integrity inGMP/GDP Environments. Pharmaceutical Inspection Co-operation Scheme; 2021.
8. TotalLab. ALCOA & ALCOA+ principles: the complete guide to pharma data integrity. TotalLab; 2026 : Total ab
9. Pharmaceutical Inspection Co-operation Scheme. Good practices for data management and integrity in regulated GMP/GDP environments (PI 041-1). Geneva: PIC/S Official Website; 2021
10. Medicines and Healthcare products Regulatory Agency. GxP data integrity guidance and definitions. London: MHRA Official Website; 2018
11. FDA/JAMA citation on Pentazocine (“DeNosaquo, 1969”): DeNosaquo N. The hallucinatory effect of pentazocine (Talwin). JAMA. 1969 Oct 20; 210(3):502. doi: 10.1001/jama.210.3.502
12. Shivantha S. Publishers’ Response to Post-Publication Concerns About Clinical Research in Women’s Health. BJOG. 2025;132.
13. Panda C. Data integrity principles ALCOA & ALCOA plus in pharma. Pharmaceutical Updates; 2019 . Available from: Pharmaceutical Updates
14. Choudhary A. ALCOA, ALCOA+ and ALCOA++ principles: ensuring data integrity. Pharmaguideline; 2026
15. Certivo Team. ALCOA+ data integrity: 9 principles for lifesciences. Certivo; 2026 [cited 2026 May 11]. Available from: Certivo
16. Shmmon Ahmad , Ashok Kumar , Abdul Hafeez , Importance of data integrity & its regulation in pharmaceutical industry, Pharma Innovation Journal ,2018
,PgNo: 306-313.
17. Rattan AK. Data Integrity: History, Regulations, and Implementation of ALCOA Plus in Pharmaceutical Industries. Journal of GXP Compliance. 2017;21(4)1-12.
18. Leal F, Chis AE, Caton S, González-Vélez H, García-Gómez JM, Durá M, et al. Smart Pharmaceutical Manufacturing: Ensuring End-to-End Traceability and Data Integrity in Medicine Production. Big Data Research. 2021;24:100172. doi:10.1016/j.bdr.2020.100172.
19. Naseem A. Charoo, Mansoor A. Khan, Ziyaur Rahman, Data Integrity Issues In Pharmaceutical Industry: Common Observations, Challenges & MitigationsStrategies , 2023.
20. M H Ingale, M C Tayade, YP Patil , RahulSalunkhe, Data IntegrityViolations in the Pharmaceutical Industry and Regulatory Measures , Internation Journal Of Pharmaceutical Quality Assurance ,2023 , Pg No : 416-420 .
21. Pedro F, Veiga F, Mascarenhas-Melo F. Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry: How obvious is it? Drug Discovery Today. 2023;28(11):103759. doi:10.1016/j.drudis.2023.103759
22. Gade S, Jadhav P, Ige P, Bornare P. Data Integrity Compliance, Importance, Consequences and Strategy to Overcome Data Integrity in the Pharmaceutical Industry. International Journal of Pharmaceutical Sciences. 2024;21122-1132. doi:10.5281/zenodo.12513412.
23. BalajiJ,JasvanthR,RagavendraSD, Bhandarkar AU.EnsuringData Integrityinthe Pharmaceutical Industry: Benefits, Challenges, Key Considerations and Best Practices. International Journal of Pharmaceutical Sciences. 2024;2:1198-1210. doi:10.5281/zenodo.13971925.
24. Mital Patel, Praful Bharadia, Piyush Patel. Patel M, Bharadia P, Patel P. Data integritybreach: A critical challenge faced bythe pharmaceutical industrythroughout the regulatory audit. IntJPharmSci.2024;2:538-550.
25. Divya Gokulakrishnan, Sowmyalakshmi Venkataraman , Ensuring dataintegrity: best practices and strategies in pharmaceutical industry, IntelligentPharmacy, 2025, Vol.3 No.4. ISSN:2949-866X, Pg No:296-303.
26. Brandser NR, Fotos J, Jiwani RS, Li MD, et al. Data integrity in the healthcare industry: implications for imaging data management and governance. J Pharm Policy Pract. 2025;18:11.
27. Chanchal Manohar Avchar, Ensuring Data Integrity In The Pharmaceutical Industry:Challenges&BestPractices,InternationalJournalofPharmaceuticalSciences
, 2025 , Vol 3.
28. Madhanraj S, Anton Smith A , ata integrity in pharmaceuticals , International Journal Of Drug Regulatory Affairs , 2025 ,ISSN : 2321-6794, Page No 26-36.
29. Mustoe CL, Turner AJ, Urwin SJ, Houson I, et al. Quality by Digital Design (QbDD): a framework to accelerate medicines development and enable regulatory innovation. 2026.
30. Salukha P, Mane C, Lumbar S, Battalwar V, Kadam K, Salunkheet S, et al. Data integrity in pharmaceutical quality systems: regulatory expectations, compliance trends, and ALCOA+ principles under Pharma 4.0. 2026.